Zheng Quan Shi Bao Wang·2025-07-04 08:41Group 1 - The innovative drug concept index rose by 0.72%, ranking 9th among concept sectors, with 108 stocks increasing in value [1][2] - Notable gainers included Guangshantang and Rejing Bio, both reaching a 20% limit up, while other significant increases were seen in Jingxin Pharmaceutical, Haizheng Pharmaceutical, and Saily Medical, with respective rises of 10.02%, 10.02%, and 18.79% [1][2] - The sector experienced a net outflow of 296 million yuan in principal funds, with 93 stocks receiving net inflows, and five stocks exceeding 100 million yuan in net inflows, led by Zhongyuan Qihua with 183 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Saily Medical, Aosaikang, and Zhongyuan Qihua, with net inflow rates of 30.63%, 29.89%, and 20.01% respectively [3] - The innovative drug sector's top performers in terms of net inflow included Zhongyuan Qihua, Guangshantang, and Aosaikang, with net inflows of 182.94 million yuan, 156.95 million yuan, and 137.87 million yuan respectively [3][4] - The overall trading activity in the innovative drug sector showed a mix of significant gains and losses, with some stocks like Anlikang and Zhenbaodao experiencing declines of 7.81% and 3.95% respectively [1][2][3]